HALO Key Statistics, Chart & Performance
The current stock price of HALO is 73.13 USD. In the past month the price increased by 15.47%. In the past year, price increased by 38.5%.
HALO Latest News, Press Relases and Analysis
HALO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.7 | 395.77B | ||
| AMGN | AMGEN INC | 15.1 | 177.79B | ||
| GILD | GILEAD SCIENCES INC | 14.82 | 150.57B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.98 | 118.84B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.25 | 81.61B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 796.86 | 53.69B | ||
| INSM | INSMED INC | N/A | 37.34B | ||
| NTRA | NATERA INC | N/A | 34.33B | ||
| BIIB | BIOGEN INC | 10.91 | 26.79B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.05 | 21.65B | ||
| INCY | INCYTE CORP | 16.61 | 20.94B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.29B |
Related stock screener links
About HALO
Company Profile
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. The company is headquartered in San Diego, California and currently employs 350 full-time employees. The company went IPO on 2003-01-30. The firm's commercially-validated solution, ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, is used to facilitate the subcutaneous delivery of injected drugs and fluids, with a focus on improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. The firm licenses its technology to biopharmaceutical companies to collaboratively develop products that combine ENHANZE with its partners’ proprietary compounds. The company also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The firm has two commercial proprietary products, Hylenex and XYOSTED. The company also has a proprietary ultra-high concentration microparticle formulation technology for biologics, branded Hypercon.
Company Info
HALOZYME THERAPEUTICS INC
12390 El Camino Real
San Diego CALIFORNIA 92121-1345 US
CEO: Helen I. Torley
Employees: 350
Phone: 18587948889
HALOZYME THERAPEUTICS INC / HALO FAQ
Can you describe the business of HALOZYME THERAPEUTICS INC?
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. The company is headquartered in San Diego, California and currently employs 350 full-time employees. The company went IPO on 2003-01-30. The firm's commercially-validated solution, ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, is used to facilitate the subcutaneous delivery of injected drugs and fluids, with a focus on improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. The firm licenses its technology to biopharmaceutical companies to collaboratively develop products that combine ENHANZE with its partners’ proprietary compounds. The company also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The firm has two commercial proprietary products, Hylenex and XYOSTED. The company also has a proprietary ultra-high concentration microparticle formulation technology for biologics, branded Hypercon.
Can you provide the latest stock price for HALOZYME THERAPEUTICS INC?
The current stock price of HALO is 73.13 USD. The price increased by 2.71% in the last trading session.
What is the dividend status of HALOZYME THERAPEUTICS INC?
HALO does not pay a dividend.
What is the ChartMill technical and fundamental rating of HALO stock?
HALO has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
On which exchange is HALO stock listed?
HALO stock is listed on the Nasdaq exchange.
Can you provide the PE ratio for HALO stock?
The PE ratio for HALOZYME THERAPEUTICS INC (HALO) is 12.99. This is based on the reported non-GAAP earnings per share of 5.63 and the current share price of 73.13 USD.
Is HALOZYME THERAPEUTICS INC (HALO) expected to grow?
The Revenue of HALOZYME THERAPEUTICS INC (HALO) is expected to grow by 33.82% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
HALO Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to HALO. When comparing the yearly performance of all stocks, HALO is one of the better performing stocks in the market, outperforming 85.2% of all stocks.
HALO Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to HALO. While HALO has a great profitability rating, there are some minor concerns on its financial health.
HALO Financial Highlights
Over the last trailing twelve months HALO reported a non-GAAP Earnings per Share(EPS) of 5.63. The EPS increased by 48.55% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 47.91% | ||
| ROA | 26.81% | ||
| ROE | 118.17% | ||
| Debt/Equity | 1.59 |
HALO Forecast & Estimates
15 analysts have analysed HALO and the average price target is 77.52 USD. This implies a price increase of 6% is expected in the next year compared to the current price of 73.13.
For the next year, analysts expect an EPS growth of 51.29% and a revenue growth 33.82% for HALO